Whitepaper: Risk-Based Approach to Development – Injectable Combination Product
Posted: 6 November 2024 | West Pharmaceutical Services | No comments yet
Drug-device combination products offer advantages for patients but are complex and challenging to develop. Establish a holistic approach to DDCP development and assess and manage risk throughout the process.
Drug-device combination products, such as injectables, can consist of a biological product and a device, a drug and a biological product, or a drug, device, and a biological product or simply a drug and a device. DDCPs leverage new technologies that provide many advantages for patients, such as self-administration conveniences, safety and, for payers, improved adherence. Injectables have experienced significant market growth, with prefilled syringes representing 32 percent of the global injectables market in 2020 and an estimated compound annual growth rate of 14.1 percent reported from 2016 to 2021.
Related content from this organisation
- Whitepaper: Risk-Based Approach to Development – Injectable Combination Product
- Delivering market success for concept to patient
- A data-driven approach to Container Closure Integrity
- CPHI Milan 2024: everything you need to know
- How ready are you? Preparing for the impact of EU GMP Annex 1 on primary packaging
